R enin (REN) is thought to be the rate-limiting enzyme controlling the generation of angiotensin II, the effector hormone of the REN-angiotensin system. The main source of circulating REN is juxtaglomerular cells of the kidney, although REN expression has been reported in a number of extrarenal tissues. Expression of REN mRNA and its release from the kidney is thought to be controlled at the transcriptional, posttranscriptional, and posttranslational level and is regulated by physiological cues such as arterial pressure, plasma sodium, and sympathetic nerve activity. 1 Although the REN-angiotensin system has been studied for decades, the molecular mechanisms controlling the regulation of REN gene expression and REN release remain unclear (reviewed in Reference 2) .
Initial clues for the existence of a major regulatory element(s) controlling REN gene expression came from a number of transgenic studies that implicated a region between Ϫ2.5 kb and Ϫ4.6 kb as controlling the spatial and temporal expression of the mouse REN (mREN) gene. [3] [4] [5] [6] [7] An enhancer of transcription was later found by deletion mutagenesis and transient transfection analysis to lie from Ϫ2866 to Ϫ2625 bp relative to the initiation of transcription of the mREN gene. 8 The studies were performed using a REN-expressing mouse kidney cell line (As4.1) sharing many properties in common with bona fide juxtaglomerular cells. 9 The enhancer can stimulate an 80-to 100-fold increase in the activity of a basal mREN promoter in these cells in an orientationand position-independent manner consistent with its definition as a classical enhancer of transcription. Moreover, reporter constructs containing the enhancer respond similarly to physiological cues controlling expression of the endogenous REN gene. 10 In contrast, studies of the human REN (hREN) gene 5Ј-flanking sequence extending to Ϫ5 kb failed to identify sequences with enhancer-like activity. Indeed, most regulatory studies initially focused on determining the importance of the relatively small transcriptional effects imparted by 2 elements close to the promoter, a cAMP-responsive element (CRE) and a POU-domain factor binding site with homology to Pit-1. [11] [12] [13] [14] Although genomic transgenes containing the entire hREN coding region and relatively small amounts of 5Ј-flanking sequence are cell-specifically expressed in renal juxtaglomerular cells, they also exhibit ectopic expression suggesting the absence of potentially important regulatory sequences. 15, 16 Moreover, reporter genes containing up to 5 kb of 5Ј-flanking sequence either are not expressed or are inappropriately expressed in transgenic mice (C.D. Sigmund, unpublished observations, 1998) . Recent studies suggest the presence of a sequence homologous to the mREN enhancer Ϸ12 kb upstream of the hREN promoter. 17 However, despite having substantial homology, transcriptional activity of DNA fragments containing the hREN enhancer-like sequence are markedly lower than corresponding fragments containing the mREN enhancer.
In this report, we examined the molecular mechanism regulating mouse and human REN enhancer activity by using chimeric mouse/human REN enhancers that were generated by taking advantage of natural sequence variation between them. Our results reveal that the promoter proximal 40 bp of the mREN enhancer is critical for its full transcription-inducing activity. Moreover, we demonstrate that this region contains both positive and negative regulatory elements and that the hREN enhancer sequence is deficient in its transcriptional activation because of a natural loss-of-function mutation in the positive element.
Materials and Methods

Plasmid Construction
Two hREN P1 artificial chromosome (PAC) clones were obtained from Genome Systems (St. Louis, Mo) by screening a PAC library with a previously described polymerase chain reaction (PCR)-amplified cDNA clone encompassing exons I through V. 18 The presence of the entire coding region of hREN was established, and a 23-kb KpnI fragment was identified by Southern blot analysis as containing the mREN enhancer homology. The 23-kb KpnI was subcloned into pBluescript II SK-to form clone 67. PAC clones were handled and PAC DNA was purified according to directions provided by the manufacturer. Similar P1 clones containing hREN were previously described. 17 A 4.1-kb 5Ј-flanking DNA of the mouse Ren-1 c gene was subcloned from RIC-4.1CAT 8 first into the pGEM-2 vector to form pGEM-m4.1K and then into pGL2-basic to form the construct m4.1kP-luc. This segment provided a positive control containing the mREN enhancer in its normal orientation and context upstream of the mREN promoter. The mREN test promoters, m2.6kP and m117P, each extending upstream to the coordinate indicated and downstream to ϩ6, were derived from pGEM-m4.1K, and cloned into pGL2-basic to form the plasmids m2.6kP-luc and m117P-luc, respectively. The hREN test promoters, h896P and h149P, derived from a longer subclone containing 2.75 kb of hREN 5Ј-flanking DNA and extending upstream to the coordinate indicated and downstream to ϩ13, were subcloned into pGL2-basic to form the plasmids h896P-luc and h149P-luc, respectively. All 4 promoters have their own endogenous mouse or human REN transcription start site. All 4 promoters were cloned upstream of the luciferase reporter gene in pGL2-basic in the forward orientation except those otherwise specified in text.
The 1018-bp PstI fragment containing the hREN enhancer homology was subcloned from clone 67 as a PstI fragment into pSL301 (Invitrogen) to form the plasmid pSL-h1018E. The hREN enhancer fragment consisting of the entire homologous region (h242E) was PCR amplified with the primers CGGGATCCACACTGGGAGAAGACCCTC and GCGCTAGCATGCTGTTGGAAATGGGGCCCC from pSL-h1018E and cloned first into pCR2.1 (Invitrogen) and then into pSL301 as a BamHI-to-SphI fragment. Both restriction sites (underlined) were engineered into the primers. The hREN enhancer fragment consisting of only the highly homologous region (h202E) was subcloned after PCR amplification of clone 67 with the following pair of oligonucleotides: GGGATCCGACACTGGGAGAAGACCCTC and CGGGATCCGC-CAGGTCACCATCTGCCTGG. The product was digested with BamHI (underlined) and cloned into h896P-luc. The minimal functional mREN enhancer fragment (m242E) was obtained from (Ϫ2625ϾϪ2866)m117-CAT as previously described 8 and subcloned into pSL301. The m40 sequence was obtained by directly cloning overlapping oligonucleotides containing the sequence GATCCTGTACTCTGACCTCTGAGTGGCT-GGTTGTGATAGCGCATG and GATCCCATGCGCTATCACAAC-CAGCCACTCAGAGGTCAGAGTACA into pBluescript-II-SK-as a BamHI fragment utilizing the BamHI sticky ends (underlined) engineered into the oligonucleotides. Each of these subcloned enhancer fragments was excised as a cassette and inserted upstream of 1 of the 4 promoter plasmids described above to generate the final transfection constructs. The sequence and orientation of all clones was confirmed by endonuclease restriction digestion and DNA sequencing.
To generate chimeric enhancers (ie, the mREN enhancer lacking the m40 element [m242E-m40] and the hREN enhancer plus the m40 element [h202ϩm40]), SmaI to BstXI fragments were exchanged between the plasmids m242E-h896P-luc and h202E-h896P-luc to form [m242E-m40]-h896P-luc and [h202Eϩm40]-h896P-luc, respectively. The SmaI-to-BstX1 fragment contains the 202-bp segment of highest homology between the mouse and human minimal enhancers. The chimeric enhancers were then subcloned upstream of the other promoters described above. The m40 segment was removed from the positive control plasmid m4.1kP-luc by cloning a SmaI-BstXI fragment from m4.1kP-luc, containing 5Ј-flanking DNA from Ϫ4.1 to Ϫ2665 kb (including m242E without m40) upstream of m2.6kP-luc.
To generate mutations in transcription factor binding sites a and b, site-directed mutagenesis was performed in the plasmid containing the entire minimal mREN enhancer (m242E) cloned into pGem-7Zf(-) (Promega). Oligonucleotides generated by Genosys Biotechnologies Inc were used for the mutagenesis after phosphorylation. Mutation in site a was generated with the mX30a oligonucleotide TGTACTCTGAC-CTCTTCGCTGCTGGTTGTG and mutation in site b was generated with the mJb oligonucleotide CAGATGGTGACCTGGCTG-TACTCTTTCCTC. The G-to-A mutation in h242E and h1018E was generated with the mX30 m1 oligonucleotide CATACTGACCTCTCA-GATCCTTGGGGCCCC. The phosphorylated selection oligonucleotide was CCGCGAGACCCACCCTTGGAGGCTCCAGATTTATC, and mutations were generated using the GeneEditor in vitro SiteDirected Mutagenesis System (Promega). The sequence of these mutations was confirmed by direct fluorescent DNA sequencing. To place the mutations in the appropriate context in the human/mouse chimeric enhancer constructs (h202ϩm40), the upstream segment of the mouse minimal enhancer (m202) was exchanged with h202 by SmaI-BstXI. The mutated enhancer sequences were then cloned upstream of the m2.6kP promoter in m2.6kP-luc.
To generate the A-to-G mutation in m242E, overlapping doublestranded oligonucleotides with the sequence GATCCTGTACTCTG-GCCTCTGAGTGGCTGGTTGTGATAGCGCATG and CGCTAT-CACAACCAGCCACTCAGAGGCCAGAGTACAG were cloned into pGem7zf(-) using the BamHI and SphI sticky ends into oligonucleotides. The mutants were then transferred to m242E by swapping an RsaI to SphI fragment containing the mutations.
Cell Culture and Transfection
The generation and characterization of the mouse kidney RENexpressing As4.1 cell line (American Type Culture Collection, CRL2193) was previously described. 9 As4.1 cells were propagated in DMEM containing 10% FBS, penicillin (100 U/mL), and streptomycin (100 g/mL). Seventy-two hours before transfection, As4.1 cells were split and cultured in 75-cm 2 flasks. Forty-eight hours before transfection, the cell culture medium was switched to Opti-MEM reduced-serum medium supplemented with 2% FBS, 1 mg/mL Albumax-II (Gibco-BRL), penicillin (100 U/mL), and streptomycin (100 g/mL). The conditioned As4.1 cells were transfected with plasmid DNA by electroporation. In brief, the cells were lifted with trypsin-EDTA solution, washed, and suspended in Dulbecco's PBS (5.0ϫ10 7 /mL). Plasmid DNA was mixed with 0.5 mL of cells (2.5ϫ10 7 ), and the cell-DNA mixture was transferred into an electroporation chamber (0.4-cm electrode spacing) and electrically shocked using a Cell Porator (Life Technologies, Inc). A single electric impulse was used at 260 V and 1180 F. After electroporation, the transfected cells were grown in a 60-mm dish containing 5 mL of the supplemented Opti-MEM reducedserum medium. After 4 hours of incubation, culture media were changed with fresh supplemented Opti-MEM reduced-serum medium. Cells were harvested and assayed for luciferase and ␤-galactosidase activities 48 hours after initial transfection.
The Rous sarcoma virus (RSV) promoter-LUC vector was always used as a standard positive control in each experiment. Test constructs were transfected in equal molar ratios using 25 g of m4.1kP-LUC as the starting point. In addition, the amount of nucleic acid in each transfection was brought to a total of 27 g using pUC19 vector DNA as a carrier. A cytomegalovirus-promoter-␤-galactosidase reporter vector (0.1 g) (a gift from Dr Andrew F. Russo, University of Iowa) was cotransfected as an internal control to monitor transfection efficiency. Plasmid DNA for transfection was prepared by using the DNA Purification System (Promega) and purified by 2 ultracentrifugation steps through cesium chloride/ethidium bromide density gradients.
Luciferase and ␤-galactosidase activity assays were performed using the Luciferase Assay System (Promega) and the Galacto-Light Plus chemiluminescent reporter assay system (Tropix Inc) according to the instructions provided by the manufacturers and as previously reported. 14 Luminescence was determined as light units on a Monolight 2010 luminometer (Analytical Luminescence Laboratory). All assays were performed in duplicate, and the average of 2 readings was used as 1 data point. Luciferase activity was normalized to ␤-galactosidase activity from the same cytoplasmic extract and expressed as a percentage of relative transcriptional activity of the RSV promoter.
Statistical Analysis
All data are presented as meanϮSEM. Data were analyzed by 1-way ANOVA with correction for multiple analyses using the Bonferroni t test. When the test for normalization failed, the analysis was performed by Kruskal-Wallace ANOVA on ranks. All analysis was performed using the using SigmaStat for Windows software package (SPSS Scientific).
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extract was prepared from As4.1 cells as previously described. 19 The concentration of the nuclear protein was determined by using the Bio-Rad Protein Assay (Bio-Rad Laboratories). Aliquots of the dialyzed nuclear extract were stored at Ϫ80°C. Double-stranded oligonucleotides were made by heating equal amounts of 2 complementary single-stranded oligonucleotides (Genosys Biotechnologies Inc) at 94°C for 5 minutes, followed by slow cooling to room temperature. The probes were made from double-stranded oligonucleotides (10 pmol) containing a 5Ј-GATC overhang at both ends using Klenow DNA polymerase incorporating [␣- o C for 15 minutes either before or after complex formation. Both antibodies were generated to N-terminal peptides. Loading dye was added to the reactions, and the binding products were resolved on a 6% nondenaturing polyacrylamide gel (40% stock; acrylamide: bisacrylamide, 19:1) in 0.25ϫ Tris borate-EDTA (pH 8.5) running buffer. 14 After electrophoresis at 4°C, the gels were dried for autoradiography.
Southern Blot Analysis
m4.1kP-LUC (100 ng) and clone 67 plasmid DNA (200 ng) was restriction digested and then run on a 0.7% agarose gel. The gel was first stained with ethidium bromide, photographed, and then blotted to a nylon-supported nitrocellulose membrane using standard procedures. The blot was probed with a single-stranded oligonucleotide matching the antisense of m40 that was labeled with 32 P by T4 polynucleotide kinase.
Results
The absence of a functional enhancer element or a sequence homologous to the mREN enhancer within the proximal 5000 bp of known 5Ј-flanking DNA sequence of the hREN gene led us to consider the possibility that an enhancer element might be present in the distal flanking regions. To test this possibility, 2 PAC clones containing the entire hREN gene were obtained from Genome Systems. Southern blot analysis using a 242-bp fragment encoding the minimal functional mREN enhancer (m242E) 8 revealed the presence of a sequence homologous to the enhancer within a 23-kb KpnI, a 3733-bp HindIII, and a 1018-bp PstI fragment ( Figure 1B ). Sequence analysis of the ends of the KpnI fragment revealed the upstream end to be new, unique sequence and the downstream anchor end to be contiguous with another KpnI fragment that spans most of the hREN coding region. Interestingly, the hREN enhancer homology is located Ϸ12 to 13 kb upstream from the hREN promoter, 9 kb farther upstream than in the mREN gene. 17 Sequence analysis of 5943 bp of hREN 5Ј-flanking DNA centering on the enhancer homology (Ϫ9 to Ϫ15 kb) revealed a number of blocks of segmental homology with the mREN 5Ј-flanking sequence between Ϫ4.1 and ϩ1 ( Figure 1A ). The blocks ranged in homology from Ͼ50% to Ͼ80% with the enhancer lying in a region of highest homology (block 7).
We first tested whether the hREN enhancer homology was functional by cloning a 1018-bp PstI fragment (h1018E) containing the homology directly upstream of 2 hREN promoters differing in length of 5Ј-flanking DNA (149 and 896 bp) fused to luciferase. As a control the minimal mREN enhancer (m242E) was also fused to the same promoters. Transient transfection analysis showed that m242E strongly enhanced hREN promoter activity (25-fold for h149P and 10-fold for h896P), whereas h1018E was much less effective in inducing the activity of either promoter (2-fold for h149P and 3-fold for h896P, Figure 2 ). This initial result suggested that the hREN enhancer homology may not function as a classical enhancer element. This may be due to the presence of a negative regulatory element in the h1018 sequence or the absence of critical elements required for full enhancer activity.
DNA sequence analysis of the minimal mREN enhancer and the 1018-bp PstI fragment revealed that the enhancer sequences shares 71% DNA-sequence identity. With respect to the promoters, the distal 202-bp portions (h202 and m202) share higher homology (80% similarity), whereas their proximal 40-bp sequences (h40 and m40) are quite different (45% similarity) ( Figure 1C ). To rule out the presence of negative regulatory elements within h1018E, we subcloned the region of highest homology between the mREN and hREN enhancers. The 202-bp distal portion of the hREN enhancer (h202E) was cloned upstream of the h149P and h896P promoters. In contrast to the h1018E sequence, h202E homology induced transcriptional activity of h149P by 19-fold in comparison with 25-fold caused by m242E, a difference of only 1.3-fold that was not statistically significant, suggesting that the h202E sequence does have intrinsic enhancer-like activity (Figure 2A ). In contrast, however, the same sequence only marginally stimulated transcription from the longer h896P promoter, suggesting that h202E does not contain all the essential cis-acting elements needed to act as a classical enhancer when placed a greater distance upstream from the promoter ( Figure 2B ). m242E and h202E differ in that m242E contains the promoter-proximal 40-bp sequence (termed m40), whereas this sequence is lacking from h202E. Recall that m40 and h40 shared Ͻ50% identity. We next tested the hypothesis that m40 may be required for full enhancer activity when it is located at a distance from the promoter. To accomplish this, we designed a set of chimeric enhancers in which m40 is removed from m242E (m242E-m40) and placed behind h202E (h202Eϩm40). We speculated that if m40 is required for full enhancer function when located a distance from the promoter, then deletion of m40 from m242E would diminish its activity, whereas addition of m40 to h202E would confer full enhancer activity when located a distance from a REN promoter. All 4 enhancers (m242E, m242E-m40, h202E, and h202Eϩm40) increased transcriptional activity of the short h149P promoter from 16-to 25-fold ( Figure 3B ). However, removal of m40 from m242E significantly lowered transcriptional induction of the longer h896P promoter from 10-fold to 3-fold ( Figure 3D ). Consistent with the hypothesis, addition of m40 to the promoter-proximal end of h202E increased promoter activity from 2-fold to 8-fold ( Figure  3D ). Similarly, only modest changes in enhancer activity were obtained when the 4 enhancer combinations were placed upstream of a short 117-bp mREN promoter (m117P, Figure 3A ).
Although the difference in enhancer-driven activity was significantly lower for h202E than for m242E, both enhancers still markedly stimulated the activity of the basal m117 promoter. However, as with the h896P promoter, elimination of m40 from m242E or its addition to h202E caused a significant change in the activity of the longer 2.6-kb mREN promoter (m2.6kP, Figure 3C ). The 3-fold change in enhancer-driven activity in response to elimination of m40 from m242E or its addition to h202E was similar on both h896P and m2.6kP. The function of m40 was further confirmed by examining the consequences of its removal from its native position within m4.1kP and comparison with m2.6kP lacking the mREN enhancer. Transcriptional induction in response to the 4.1-kb segment of mREN 5Ј-flanking DNA lacking m40 was 3-fold lower than that of intact m4.1kP ( Figure 4A ). These data suggest that m40, although not absolutely required for full enhancer activity when the REN enhancer is placed close to a REN promoter, is required for full enhancer activity when located a distance from the promoter. Interestingly, the m40 segment on its own does not have significant intrinsic enhancer activity when placed upstream of either a short or long mREN or hREN promoter ( Figure 4B ). 
and P, PstI. C, An alignment between the mouse and human REN enhancer sequences. Alignment was performed using MegAlign from the DNA*Star DNA sequence analysis package. * indicates identical nucleotides, and _, missing bases. The m40 sequence is underlined, and the critical A/G residue within element b is in the shaded box. The mouse and human enhancer sequences have been deposited in GenBank (accession Nos. AF140237 and AF140238, respectively).
We next used EMSAs to identify DNA-protein interactions that may regulate the function of m40. EMSAs were performed using double-stranded DNA oligonucleotides encoding the m40 sequence and nuclear extracts prepared from As4.1 cells. These studies revealed the formation of 2 major complexes on m40, labeled a and b, which were efficiently competed by increasing molar excess of unlabeled m40 oligonucleotide ( Figure 5 ). The specificity of binding was confirmed by the inability of 3 different unrelated oligonucleotides (encoding the hREN CRE and activator protein 1 and 2 consensus sequences) to compete for m40 binding (data not shown). To begin to narrow down the location of the 2 complexes on m40, competition was performed using two 30-bp overlapping double-stranded oligonucleotides, mX30 and mY30. Complexes a and b were both easily competed with mX30, but not with mY30 ( Figure 5 ), suggesting that the 2 specific DNA-nuclear protein complexes require sequences on the promoter distal portion of m40.
We next assessed which bases are important for the DNAnuclear protein interactions by EMSA and competition using mutant oligonucleotides. In the first experiment, we introduced 9 sequential 3-bp deletion mutations in mX30, generating 9 different double-stranded mutant oligonucleotides (1 to 9 in Figure 6A ). Deletion mutants 1, 2, 8, and 9 were able to efficiently compete for both complexes a and b ( Figure 6B ). Mutants 3 to 7 were unable to effectively compete for complex a, whereas mutants 3 and 4 were unable to compete for complex b. These data suggest that 2 sequence motifs, GACCTCT-GAGTGGCT and GACCTC, form complexes a and b, respectively, with nuclear extracts from As4.1 cells. Interestingly, sites a and b appear to overlap (see below).
Oligonucleotides with specific base-substitution mutations were then used as competitors to confirm these findings ( Figure  6A ). We made 3 mutant oligonucleotides in mX30. The mX30a contains a 4-base change of the central GAGTG motif to TCGCT. These residues were selected to avoid the region overlapped by element b. The mX30b oligonucleotide contains a 2-nucleotide change from GACCTC to TTCCTC, and mX30ba contains both mutations. mX30a lost its ability to compete for complex a but not b, mX30b lost its ability to Figure 2 . Transcriptional activity of the hREN and mREN enhancer sequences. Transcriptional activities (% RSV-luc) of the m242E, h1018E, and h202E sequences upstream of the h149P promoter (A) and h896P promoter (B) are shown. P indicates promoter alone; Pϩm242E, indicated promoter plus m242E sequence; Pϩh1018E, indicated promoter plus h1018E sequence; and Pϩh202E, indicated promoter plus h202E sequence. Numbers in parentheses indicate fold induction over promoter. The purpose of this experiment was to compare enhancer-driven activity of the h1018E and h202E sequences with the mouse minimal enhancer. Therefore, statistical analysis was performed by comparing the fold induction (in independent experiments) of the indicated plasmids with Pϩm242E as control. *PϽ0.05 vs Pϩm242E; nϭ8 for all constructs. Shown are transcriptional activities (% RSV-luc) of the m242E and h202E sequences as well as chimeric enhancers (m242E-m40 and h202Eϩm40) upstream of the m117P promoter (A), h149P promoter (B), m2.6kP promoter (C), and h896P promoter (D). P indicates promoter alone; m242E, indicated promoter plus m242E sequence; m242E-m40, indicated promoter plus chimeric m242E lacking m40 sequence; h202E, indicated promoter plus h202E sequence; h202Eϩm40, indicated promoter plus chimeric h202E enhancer containing m40 element. Numbers in parentheses indicate fold induction over promoter alone. The purpose of this experiment was to compare m40-containing and m40-lacking enhancers with the mouse minimal enhancer. Statistical analysis was therefore performed by comparing the fold induction of the indicated plasmids with Pϩm242E as control. *PϽ0.05 vs m242E; nϭ6 for constructs in panel A, nϭ8 for constructs in panels B and D, and nϭ7 for constructs in panel C. .1kP-m40-LUC was generated by an internal deletion of m40 within the intact 4.1-kb 5Ј-flanking sequence of the mouse Ren-1 c gene cloned upstream of luciferase. Transcriptional activities (% RSV-luc) of the m2.6kP promoter, the m4.1kP promoter, and a mutation in m4.1kP eliminating the m40 element (m4.1kP-m40) are shown. Numbers in parentheses indicate fold induction over promoter alone. The purpose of this experiment was to compare the importance of the m40 sequence on the transcriptional induction caused by the enhancer. Statistical analysis was performed by comparing the fold induction of m4.1kP with Pϩm4.1kP as control. *PϽ0.05 vs m4.1kP-m40; nϭ8 for all constructs. B, DNA sequence of m40 was cloned upstream of the m117P (nϭ6), m2.6kP (nϭ8), h896P (nϭ8), and h149P (nϭ8) promoters. Open bars, promoter alone; closed bars, indicated promoter plus m40 element. *PϽ0.05 vs promoter alone (Student t test).
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compete for complex b but not a, and mX30ba cannot effectively compete for either complex, clearly demonstrating the specificity of the binding and the location of binding sites ( Figure 6C ). The binding site for complex a has homology with the binding site for NF-Y, a ubiquitous CAAT-box transcription factor. The homology extends over the entire 14-bp recognition sequence (NCTGATTGGYTASY) except for 1 nucleotide within the core binding region (AGTGG for ATTGG), which forms the CCAAT motif on the antisense strand and is invariant in other NF-Y binding sites. To test whether complex a involves NF-Y, we first performed EMSA analysis using mX30 as a probe and a series of competitors ( Figure 7A ). Both mX30 and a mutant replacing the G with the invariant T in other NF-Y binding sites competed for complex a formation. In addition, the wild-type NF-Y site from the major histocompatibility class II E␣ gene competed for complex a formation, whereas a mutant NF-Y site did not. 20, 21 Moreover, neither wild-type nor mutant binding sites for CRE binding protein competed for complex a (or complex b). The formation of a complex between site a and NF-Y was further validated by supershift analysis ( Figure 7B) . A strong supershift was observed with antisera to NF-Y subunit A (NF-Ya), and a weak but detectable supershift was obtained with antisera to NF-Y subunit B (NF-Yb). A stronger supershift with the NF-Yb antisera was obtained after an extended incubation with nuclear proteins (data not shown). Both antibodies supershifted complex a when added to nuclear proteins either before or after DNA:protein complex formation.
To experimentally test the function of these binding sites in vivo, we generated a series of base-substitution and -deletion mutations in the m40 segment of m242E using site-directed mutagenesis. The same m40a, m40b, and m40ab mutations used for the EMSA experiments were placed upstream of the m2.6kP-luc reporter. Importantly, by using the m2.6kP promoter, we are retaining the normal positioning of the enhancer relative to the mREN promoter. As in previous experiments, m242E caused a significant induction of promoter activity that was significantly attenuated by the removal of the m40 sequence ( Figure 8A ). Mutation of site b (or of both sites a and b together) attenuated enhancer-driven activity similar to that caused by the loss of the entire m40 segment, suggesting that the activity of m40 is dependent on complex b. Indeed, there was no statistically significant difference in the transcriptional induction caused by m242E-m40 and m242Eb. Interestingly, mutation of the NF-Y binding site (m242Ea) resulted in increased enhancer activity, suggesting that complex a may play a role in regulating the activity of the mREN enhancer. That complex b is necessary for this induction is evidenced by the loss of enhancer activity in the double mutant (m242Eab).
We showed above that the m40 sequence can confer increased enhancer-driven activity to h202E when placed a distance upstream from a REN promoter (Figure 3) . We therefore asked whether this property requires protein binding to element b. To accomplish this, we replaced the m40 element in the chimeric enhancer, h202Eϩm40, with the m40a, m40b, and m40ba mutants and then inserted them upstream of the m2.6kP-luc reporter construct. As above, addition of m40 to H202E significantly increased enhancer activity, and this was further increased by the mutation of the NF-Y binding site ( Figure 8B ). However, removal of complex b (or a and b) results in an attenuation of the enhancer activity stimulated by addition of m40. Again, there was no significant difference in enhancer activity between h202E and h202Eϩm40b, both of which lack element b.
The data presented above indicate that site b and the nuclear proteins binding to it can account for the stimulating function of m40. Removal of site b attenuates (1) the activity of the mREN minimal enhancer and (2) the increase in transcriptional activity caused by the addition of m40 to the hREN enhancer homology. We therefore asked whether the 40-bp segment immediately downstream of the h202E functions similarly to m40. Recall that h40 and m40 share Ͻ50% overall sequence identity and that a 1018-bp PstI fragment containing the entire hREN enhancer homology (including h40) failed to stimulate transcription (Figure 2) . Moreover, Southern blot analysis revealed the absence of a sequence homologous to m40 within a 23-kb KpnI restriction fragment containing hREN 5Ј-flanking DNA from approximately Ϫ23 kb to Ϫ149, whereas it was easily detected in the control plasmid containing 4.1 kb of mREN 5Ј-flanking DNA (Figure 9 ). Sequence analysis of h40 revealed that it contains a complex b binding site similarly positioned but with a single nucleotide mismatch (GGCCTC) compared with complex b in m40 (GACCTC). The data in Figure 6C indicate this to be 1 of 2 sites that when mutated (GACCTC to TTCCTC) result in loss of complex b formation. Indeed, the hX30 oligonucleotide (analogous to mX30 used in Figure 5 ) fails to compete for complex b formation unless an oligonucleotide containing a reversion mutation generating a G-to-A transition within the complex b binding site is used (Figure 10) . Similarly, mutation of GACCTC to GGCCTC in m40 causes a loss of competition for complex b and significantly attenuates the activity of the m242E enhancer in As4.1 cells ( Figure  11A ). The loss of activity in the A-to-G mutant is similar to that caused by the m40b mutation tested above.
Finally, we made a set of chimeric enhancers to examine whether h40 has any m40-like function. As above, the chimeric enhancers were placed at the native position of the mREN enhancer upstream of the m2.6kP promoter. The results indicate that addition of h40 to the h202E sequence (to form h242E) does not induce an increase in promoter activity ( Figure 11B) . However, a G-to-A mutation restoring the GACCTC motif in h40 results in a marked increase in enhancer activity when placed upstream of the m2.6kP promoter ( Figure 11B ) and when introduced in the h1018-bp PstI fragment ( Figure 11C ). It is interesting to note that enhancer activity in the G-to-A mutants is greater than the activity of the minimal mREN enhancer (m242E). It is therefore not surprising to note that (1) the positionally equivalent site a in h40 differs from site a in m40 at 3 of 9 bases, including 3 of the 4 positions that are mutated in m40A; (2) the hX30 oligonucleotide cannot effectively compete for complex a formation ( Figure 10) ; and (3) the increase in transcription in the G-to-A mutants is similar to that induced by mutation of site a in m40 ( Figure 11B ). A, Transcriptional activities (% RSV-luc) of the m242E and m242E mutants placed upstream of the m2.6kP promoter. P indicates promoter alone; m242E and m242E-m40 are as previously described. The mutant constructs m242Ea, m242Eb, and m242Eab are identical to m242E except for containing the same mutations as used in Figure 6C . B, Transcriptional activities (% RSV-luc) of the h202E and h202Eϩm40 mutants placed upstream of the m2.6kP promoter are shown. P indicates promoter alone; h202E and h202Eϩm40 are as described in Figure 3 . The mutant constructs h202Eϩm40a, h202Eϩm40b, and h202Eϩm40ab are identical to h202Eϩm40 except for containing the same mutations as used in Figure 6C . The numbers in parentheses indicate fold induction over promoter alone. The purpose of this experiment was to compare the enhancer-mediated induction of elements a and b with a segment that lacks these elements. Therefore, statistical analysis was performed by comparing the fold induction of the various mutant and wild-type enhancers with m242E-m40 (A) and h202E (B) as controls, both of which lack a functional m40 sequence. *PϽ0.05; nϭ6 for all constructs.
Discussion
Classical transcriptional enhancers are position-and orientationindependent cis-acting DNA elements, and the mREN gene enhancer functions as a classical enhancer. 8 A homologous enhancer-like sequence was found 12 to 13 kb upstream of the human REN promoter. 17 Although an hREN sequence containing the minimal homologous region could stimulate the activity of short REN promoters, it failed to induce transcriptional activity when placed farther upstream from the promoter. The data imply that sequences present in the mREN enhancer but lacking in the homologous hREN sequence are required for enhancer activity over a distance. Using a set of chimeric enhancers and REN promoter/5Ј-flanking sequences of differing length, we demonstrated that the promoter-proximal 40 bp of the mREN enhancer is required to mediate full transcriptional induction of the enhancer, without having intrinsic enhancer activity itself. Mutagenesis studies identified the element as a hexanucleotide containing the sequence GACCTC. Evidence supporting the importance of this sequence include the following: (1) mREN enhancer mutations that result in a loss of complex b formation are correlated with the loss of transcriptional induction, (2) mutation of element b in m40 disrupts its ability to transactivate when coupled with the h202 element, and (3) the hREN enhancer has a single nucleotide natural loss-offunction mutation in this sequence that when reverted rescues transcriptional induction. A search of the transcription factor database revealed some homology with CRE and the binding site for activating transcription factor, although element b differed from both of these in at least 1 position invariant among the consensus sequence. However, a consensus CRE failed to compete for complex b formation, suggesting that neither CREB nor other members of the activating transcription factor family contribute to complex b. The mREN enhancer functions as a classical enhancer of transcription when intact, but is highly sensitive to distance effects when element b is mutated. Numerous examples of functional synergism between transcription factors in enhancermediated transcriptional activation have been reported. [22] [23] [24] [25] That m40 does not itself have intrinsic enhancer activity makes it tempting to speculate that complex b may cooperate with other transcription factors that bind to the enhancer to activate transcription from a REN promoter. Among these may be additional sites for the formation of complex b, as sequence analysis identified 2 other stretches containing the GACCT heptanucleotide identified within element b (GACCTC). Interestingly, one of these motifs (termed element c) is present 16 bp upstream from element b. With a spacing of 1 to 2 turns of the helix it is possible that GACCT-bound nuclear factors may interact with each other as a multimer. If this is proven to be the case, the interaction of the GACCT nuclear protein(s) could be the molecular foundation for the functional synergism between the m40 and m202. Preliminary results suggest that mutation of element c has the same effect as mutation of element b, suggesting that both sites are required for enhancer activity (Q. Shi and C.D. Sigmund, unpublished observation, 1999) . Nevertheless, it is also possible that the GACCT-bound nuclear protein(s) might cooperate with other nuclear protein(s) that bind elsewhere in the enhancer. Indeed, preliminary results suggest the formation of at least 5 different DNA:protein complexes on the mREN enhancer (T.A. Black and K.W. Gross, unpublished observation, 1998).
The fact that element b is not required when the enhancer is close to the promoter perhaps suggests that direct contacts between enhancer binding proteins and proximal promoter binding proteins could take place when they are physically close to each other. Given that element b is required for enhancer activity when placed at a distance from the promoter suggests, but does not prove, that it may be required for the formation of a higher-order transcription complex involving not only enhancer-binding proteins, but also proteins binding close to the promoter. It is tempting to speculate that complex b might be involved in protein-protein interactions between the enhancer and proximal promoter that would bring them in close proximity (ie, through the formation of a loop in genomic DNA). A transcription factor identified to bind to a conserved AT-rich sequence at Ϫ60 with respect to the transcription start site may be a potential candidate, as mutations in that sequence severely diminish enhancer activity. 8 We also identified a second functional element in m40, element a, mutation of which markedly enhanced transcriptional induction of the enhancer. These results suggest that element a may act as a negative regulator of the enhancer. Potential mechanisms include the following: (1) competition for sequences in the m40 segment by proteins binding to elements a and b, where formation of complex a precludes the binding and formation of complex b, and (2) formation of complex a having some direct negative effect on formation of the transcription complex or initiation of transcription independent of complex b. Experiments are currently in progress to distinguish these mechanisms. We currently favor the former mechanism, because the induction of transcription caused by mutation of element a required a functional element b. This mechanism is not unique, given that 2 partially overlapped binding sites (one for hepatocyte nuclear factor 4 and the other for Sp1) compete for binding in the promoter region of the blood coagulation factor X gene, 26 and DNA-bound Oct-1 inhibits IL-8 promoter activity by competing against the positive nuclear factor C/EBP. 27 Interestingly, a search of the transcription factor database revealed homology between sequences within element a and the binding site for NF-Y. Element a was homologous in 12 of 13 nucleotides with a NF-Y binding site but was different at one position (CTGAGTGGCTGGT) that is invariant in other known NF-Y binding sites in the database. Despite this invariant base, both competition and supershift assays clearly identified NF-Y as the protein binding to element a. NF-Y is a ubiquitous transcription factor that acts as a CCAAT-box binding protein and is generally thought to impart a positive influence on transcription initiation by facilitating the binding of additional transcription factors to nearby promoter elements. 28, 29 CCAAT has also been reported to exert negative effects on transcription of the varicella-zoster virus immediate-early 62 promoter and the human CYP1A1 gene. 30, 31 NF-Y was also demonstrated to negatively regulate the transcriptional activity of the transforming growth factor-␤ receptor gene in embryonal carcinoma cells. 32 Our data suggest that a complex regulatory circuit may be operating to regulate the mREN enhancer and therefore transcriptional activity of the mREN gene in As4.1 cells and perhaps in JG cells in vivo. Clearly, this leaves unresolved the function, if any, of the enhancer sequence upstream of the hREN gene. The hREN enhancer homology lies an additional 10 kb upstream compared with the mREN enhancer. This suggests that the hREN enhancer may function over a large distance. However, we demonstrated that the homologous element b upstream of hREN is nonfunctional because of a single nucleotide substitution and that reversion of that mutation in either a minimal enhancer (h242E) or a larger fragment (h1018E) caused marked transcriptional induction. No other regulatory elements closely linked to the enhancer homology could substitute for the loss of element b function, because a 3733-bp HindIII fragment containing the enhancer was also unable to stimulate transcription of a REN promoter (data not shown). It is possible that the lack of function of element b in hREN (GGCCTC) is caused by an experimental artifact of its analysis in a mouse cell line. In light of this possibility, it is important to point out that both h202E and h242E had minimal effects (either no induction or 1.2-fold induction) on the transcriptional activity of the h896 promoter in Calu-6 cells, the only permanent cell line expressing human REN mRNA endogenously (data not shown), indeed suggesting that our findings are not due to artifacts of the experimental system. 14, [33] [34] [35] It is further surprising that in addition to element b, there was no evidence for a functional element a in the hREN enhancer sequence. Of course, if element b has been rendered nonfunctional, there would be little need for another element to regulate its activity. This suggests the provocative hypothesis that the hREN enhancer is itself nonfunctional or does not act as a classical enhancer of hREN transcription. If so, there would be little selective pressure to maintain its position and sequence as suggested by mutational analysis. Circulating levels of REN in humans are substantially lower than those in mice, suggesting less of a demand to maintain high-level transcription of the hREN gene. It is also possible that transcription of the hREN gene depends on additional sequences present between Ϫ13kb and the promoter. Our Southern blot analysis suggests the absence of an additional m40-like sequence in this region. However, Germain et al 36 recently identified an additional transcriptional enhancer in the hREN gene that is active in chorionic cells. In vivo, there may be cooperation between transcription factors binding to the "kidney" and "chorionic" enhancers to regulate hREN transcription, and experiments to directly test this possibility are in progress. Indeed, it is interesting to note that large hREN transgenes containing 5Ј-flanking DNA extending past the hREN enhancer (and containing both enhancer sequences) are expressed in a highly tissue-specific, cell-specific, and regulated manner. 37, 38 
